Lixte Biotechnology Holdings, Inc. reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere(R)).

Lixte Biotechnology Holdings, Inc. filed its 10-K on Mar 15, 2013 for the period ending Dec 31, 2012. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Lixte Biotechnology Holdings, Inc. announces the appointment of Kathleen Mullinix, PhD to the company's Board of Directors. From 2003 to 2006 Dr. Mullinix was an independent consultant on health sciences and biotechnology and in 2008 joined WellGen, Inc. as CEO, President and Director. Subsequently she continued her consulting, and joined the Office of Technology and Business Development, Mount Sinai School of Medicine, New York, in 2009 and became director of the office in 2010 serving to 2012.